Tre (3%) af de 91 patienter i Vc+M+P- behandlingsgruppen, der fik profylatisk behandling med antivirale stoffer, udviklede herpes zoster- reaktivering.
Three (3%) of the 91 patients in the Vc+M+P treatment group who received prophylactic antivirals developed herpes zoster reactivation.